查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1489278

全球细胞和基因治疗临床试验服务市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Cell & Gene Therapy Clinical Trial Services Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

全球细胞和基因治疗临床试验服务市场的需求预计将从2023年的45.3亿美元达到2032年近118.9亿美元的市场规模，2024-2032年研究期间的复合年增长率为11.32%。

细胞和基因治疗临床试验服务支持开发和测试需要修改基因或细胞来管理或预防疾病的创新疗法。这些服务涵盖各种活动，包括病患招募、监管合规、治疗药物的製造和临床试验管理。透过确保安全、合乎道德和高效地进行试验，它们对于将科学突破转化为可行的疗法至关重要。这些服务的提供者与研究人员、製药公司和医疗机构密切合作，以应对细胞和基因治疗试验的复杂局面，最终旨在将新的、拯救生命的治疗方法推向市场。

市场动态

研究和开发活动的激增以及对创新治疗方案不断增长的需求推动了对细胞和基因治疗临床试验服务的需求。公司和学术机构正在投入大量资金推动这些突破性的疗法，导致全球临床试验的热潮。遗传性疾病和慢性病的流行进一步凸显了有效细胞和基因疗法的迫切性，推动了对全面临床试验服务支持其发展的需求。细胞和基因转化彻底改变医疗保健的潜力仍然存在，推动了对临床研究的持续兴趣和投资。产业利益相关者、监管机构和研究机构之间的合作对于推进细胞和基因治疗临床试验服务至关重要。然而，严格的监管要求和复杂的伦理考虑可能会挑战未来几年细胞和基因治疗临床试验服务市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球细胞和基因治疗临床试验服务市场的各个细分市场进行了包容性评估。细胞和基因治疗临床试验服务产业的成长和趋势为这项研究提供了整体方法。

市场区隔

细胞和基因治疗临床试验服务市场报告的这一部分提供了国家和地区层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按服务

  • 临床试验设计与规划
  • 供应及物流服务
  • 监管事务与合规
  • 数据管理和生物统计学
  • 现场管理和监控
  • 其他服务

按阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

按指示

  • 肿瘤学
  • 血液学
  • 内分泌/代谢紊乱
  • 传染性疾病
  • 神经病学
  • 心血管疾病
  • 肌肉骨骼疾病
  • 其他适应症

按治疗类型

  • 基因治疗
  • 细胞疗法
  • 基因修饰细胞疗法

按最终用途

  • 製药与生物技术公司
  • 合约研究组织
  • 学术及研究机构
  • 其他最终用户

区域分析

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的细胞和基因治疗临床试验服务市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。细胞和基因治疗临床试验服务市场的主要参与者包括 Advarra、Charles River Laboratories International Inc.、Catalent Pharma、ICON PLC、IQVIA、Medpace Inc.、Novotech、Precision Medicine Group LLC、Parexel International、Syneos Health、Sharp Services LLC 、Thermo Fisher Scientific Inc.、全球临床试验。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：细胞和基因治疗临床试验服务 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按服务分類的市场吸引力分析
    • 按阶段分析市场吸引力
    • 按指标进行的市场吸引力分析
    • 按治疗类型分類的市场吸引力分析
    • 按最终用途分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球细胞和基因治疗临床试验服务市场分析：按服务分类

  • 按服务概览
  • 历史和预测数据
  • 按服务分析
  • 临床试验设计与规划
  • 供应及物流服务
  • 监管事务与合规
  • 数据管理和生物统计学
  • 现场管理和监控
  • 其他服务

第 6 章：全球细胞与基因治疗临床试验服务市场分析：依阶段

  • 按阶段概述
  • 历史和预测数据
  • 按阶段分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第 7 章：全球细胞与基因疗法临床试验服务市场分析：按适应症分类

  • 按指示概述
  • 历史和预测数据
  • 按指标分析
  • 肿瘤学
  • 血液学
  • 内分泌/代谢紊乱
  • 传染性疾病
  • 神经病学
  • 心血管疾病
  • 肌肉骨骼疾病
  • 其他适应症

第 8 章：全球细胞和基因治疗临床试验服务市场分析：按治疗类型

  • 按治疗类型概述
  • 历史和预测数据
  • 依治疗类型分析
  • 基因治疗
  • 细胞疗法
  • 基因修饰细胞疗法

第 9 章：全球细胞与基因疗法临床试验服务市场分析：依最终用途分类

  • 按最终用途分类的概述
  • 历史和预测数据
  • 按最终用途分析
  • 製药与生物技术公司
  • 合约研究组织
  • 学术及研究机构
  • 其他最终用户

第 10 章：全球细胞和基因治疗临床试验服务市场分析：按地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 11 章：细胞与基因疗法临床试验服务公司的竞争格局

  • 细胞与基因治疗临床试验服务市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 12 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Advarra
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Charles River Laboratories International Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Catalent Pharma
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • ICON PLC
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • IQVIA
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Medpace Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Novotech
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Precision Medicine Group LLC
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Parexel International
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Syneos Health
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Sharp Services LLC
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Thermo Fisher Scientific Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Worldwide Clinical Trials
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR112114672

The global demand for Cell & Gene Therapy Clinical Trial Services Market is presumed to reach the market size of nearly USD 11.89 Billion by 2032 from USD 4.53 Billion in 2023 with a CAGR of 11.32% under the study period 2024-2032.

Cell and gene therapy clinical trial services support developing and testing innovative treatments that entail modifying genes or cells to manage or prevent diseases. These services encompass a variety of activities, including patient recruitment, regulatory compliance, manufacturing of therapeutic agents, and clinical trial management. They are crucial in translating scientific breakthroughs into viable therapies by ensuring trials are conducted safely, ethically, and efficiently. Providers of these services work closely with researchers, pharmaceutical companies, and healthcare institutions to navigate the complex landscape of cell and gene therapy trials, ultimately aiming to bring new, life-saving treatments to market.

MARKET DYNAMICS

The surge in research and development activities and the growing demand for innovative treatment options have propelled the demand for cell and gene therapy clinical trial services. Companies & academic institutions are spending heavily in advancing these groundbreaking therapies, leading to an upsurge in clinical trials worldwide. The spurring prevalence of genetic disorders & chronic diseases further underscores the urgency for effective cell and gene therapies, driving the need for comprehensive clinical trial services to support their development. The potential of cell & gene transformation to revolutionize healthcare persists, driving sustained interest and investment in clinical research. Collaborations between industry stakeholders, regulatory bodies, and research institutions are crucial for advancing cell and gene therapy clinical trial services. However, stringent regulatory requirements and complex ethical considerations may challenge the growth of the cell and gene therapy clinical trial services market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cell & Gene Therapy Clinical Trial Services. The growth and trends of Cell & Gene Therapy Clinical Trial Services industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cell & Gene Therapy Clinical Trial Services market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Service

  • Clinical Trial Design & Planning
  • Supply & Logistics Services
  • Regulatory Affairs & Compliance
  • Data Management & Biostatistics
  • Site Management & Monitoring
  • Other Services

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • Oncology
  • Hematology
  • Endocrine/metabolic Disorders
  • Infectious Diseases
  • Neurology
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Other indications

By Therapy Type

  • Gene Therapy
  • Cell Therapy
  • Gene Modified Cell Therapy

By End-Use

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes
  • Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cell & Gene Therapy Clinical Trial Services market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cell & Gene Therapy Clinical Trial Services market include Advarra, Charles River Laboratories International Inc., Catalent Pharma, ICON PLC, IQVIA, Medpace Inc., Novotech, Precision Medicine Group LLC, Parexel International, Syneos Health, Sharp Services LLC, Thermo Fisher Scientific Inc., Worldwide Clinical Trials. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CELL & GENE THERAPY CLINICAL TRIAL SERVICES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Service
    • 3.7.2 Market Attractiveness Analysis By Phase
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Therapy Type
    • 3.7.5 Market Attractiveness Analysis By End-Use
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY SERVICE

  • 5.1. Overview By Service
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Service
  • 5.4. Clinical Trial Design & Planning Historic and Forecast Sales By Regions
  • 5.5. Supply & Logistics Services Historic and Forecast Sales By Regions
  • 5.6. Regulatory Affairs & Compliance Historic and Forecast Sales By Regions
  • 5.7. Data Management & Biostatistics Historic and Forecast Sales By Regions
  • 5.8. Site Management & Monitoring Historic and Forecast Sales By Regions
  • 5.9. Other Services Historic and Forecast Sales By Regions

6. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY PHASE

  • 6.1. Overview By Phase
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Phase
  • 6.4. Phase I Historic and Forecast Sales By Regions
  • 6.5. Phase II Historic and Forecast Sales By Regions
  • 6.6. Phase III Historic and Forecast Sales By Regions
  • 6.7. Phase IV Historic and Forecast Sales By Regions

7. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY INDICATION

  • 7.1. Overview By Indication
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Indication
  • 7.4. Oncology Historic and Forecast Sales By Regions
  • 7.5. Hematology Historic and Forecast Sales By Regions
  • 7.6. Endocrine/metabolic Disorders Historic and Forecast Sales By Regions
  • 7.7. Infectious Diseases Historic and Forecast Sales By Regions
  • 7.8. Neurology Historic and Forecast Sales By Regions
  • 7.9. Cardiovascular Diseases Historic and Forecast Sales By Regions
  • 7.10. Musculoskeletal Disorders Historic and Forecast Sales By Regions
  • 7.11. Other indications Historic and Forecast Sales By Regions

8. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY THERAPY TYPE

  • 8.1. Overview By Therapy Type
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Therapy Type
  • 8.4. Gene Therapy Historic and Forecast Sales By Regions
  • 8.5. Cell Therapy Historic and Forecast Sales By Regions
  • 8.6. Gene Modified Cell Therapy Historic and Forecast Sales By Regions

9. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY END-USE

  • 9.1. Overview By End-Use
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By End-Use
  • 9.4. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
  • 9.5. Contract Research Organizations Historic and Forecast Sales By Regions
  • 9.6. Academic & Research Institutes Historic and Forecast Sales By Regions
  • 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL CELL & GENE THERAPY CLINICAL TRIAL SERVICES MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE CELL & GENE THERAPY CLINICAL TRIAL SERVICES COMPANIES

  • 11.1. Cell & Gene Therapy Clinical Trial Services Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF CELL & GENE THERAPY CLINICAL TRIAL SERVICES INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Advarra
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Charles River Laboratories International Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Catalent Pharma
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. ICON PLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. IQVIA
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Medpace Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Novotech
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. Precision Medicine Group LLC
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Parexel International
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Syneos Health
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. Sharp Services LLC
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Thermo Fisher Scientific Inc.
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments
  • 12.15. Worldwide Clinical Trials
    • 12.15.1 Company Overview
    • 12.15.2 Company Revenue
    • 12.15.3 Products
    • 12.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Service (USD MN)
  • Clinical Trial Design & Planning Market Sales By Geography (USD MN)
  • Supply & Logistics Services Market Sales By Geography (USD MN)
  • Regulatory Affairs & Compliance Market Sales By Geography (USD MN)
  • Data Management & Biostatistics Market Sales By Geography (USD MN)
  • Site Management & Monitoring Market Sales By Geography (USD MN)
  • Other Services Market Sales By Geography (USD MN)
  • Analysis By Phase (USD MN)
  • Phase I Market Sales By Geography (USD MN)
  • Phase II Market Sales By Geography (USD MN)
  • Phase III Market Sales By Geography (USD MN)
  • Phase IV Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Hematology Market Sales By Geography (USD MN)
  • Endocrine/metabolic Disorders Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Cardiovascular Diseases Market Sales By Geography (USD MN)
  • Musculoskeletal Disorders Market Sales By Geography (USD MN)
  • Other indications Market Sales By Geography (USD MN)
  • Analysis By Therapy Type (USD MN)
  • Gene Therapy Market Sales By Geography (USD MN)
  • Cell Therapy Market Sales By Geography (USD MN)
  • Gene Modified Cell Therapy Market Sales By Geography (USD MN)
  • Analysis By End-Use (USD MN)
  • Pharmaceutical & Biotechnology Companies Market Sales By Geography (USD MN)
  • Contract Research Organizations Market Sales By Geography (USD MN)
  • Academic & Research Institutes Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Cell & Gene Therapy Clinical Trial Services Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cell & Gene Therapy Clinical Trial Services Report
  • Market Research Process
  • Market Research Methodology
  • Global Cell & Gene Therapy Clinical Trial Services Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Service
  • Market Attractiveness Analysis By Phase
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Therapy Type
  • Market Attractiveness Analysis By End-Use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Service (USD MN)
  • Clinical Trial Design & Planning Market Sales By Geography (USD MN)
  • Supply & Logistics Services Market Sales By Geography (USD MN)
  • Regulatory Affairs & Compliance Market Sales By Geography (USD MN)
  • Data Management & Biostatistics Market Sales By Geography (USD MN)
  • Site Management & Monitoring Market Sales By Geography (USD MN)
  • Other Services Market Sales By Geography (USD MN)
  • Global Market Analysis By Phase (USD MN)
  • Phase I Market Sales By Geography (USD MN)
  • Phase II Market Sales By Geography (USD MN)
  • Phase III Market Sales By Geography (USD MN)
  • Phase IV Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Hematology Market Sales By Geography (USD MN)
  • Endocrine/metabolic Disorders Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Cardiovascular Diseases Market Sales By Geography (USD MN)
  • Musculoskeletal Disorders Market Sales By Geography (USD MN)
  • Other indications Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy Type (USD MN)
  • Gene Therapy Market Sales By Geography (USD MN)
  • Cell Therapy Market Sales By Geography (USD MN)
  • Gene Modified Cell Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Use (USD MN)
  • Pharmaceutical & Biotechnology Companies Market Sales By Geography (USD MN)
  • Contract Research Organizations Market Sales By Geography (USD MN)
  • Academic & Research Institutes Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.